Investigational product accountability is the investigator's record of every unit of study product, from receipt to dispensing to return or destruction, and FDA reads it against everything else at the site. Under 21 CFR 312.62(a) the investigator must keep "adequate records of the disposition of the drug, including dates, quantity, and use by subjects." In July 2026 FDA sent a warning letter to a clinical investigator whose accountability log, dosing logs and electronic data capture disagreed for six subjects, and whose returned kits still had their tamper seals intact. The lesson for a site is plain: accountability is not a log you complete before the monitor arrives. It is a reconciliation you run every month, across the log, the case history, the EDC and the product in your hand.
In short
- 692 clinical investigator inspections in FY 2024; 156 ended with a Form 483, about 23% (FDA, 2025).
- 6 subjects in the July 27, 2026 warning letter had dosing logs, accountability records and EDC entries that did not agree (FDA Law Blog, 2026).
- 3 duties stay with the investigator when product ships to a participant's home: authorize release, ensure receipt, document return or disposal (FDA, 2024).
- 1°C outside range for more than 30 minutes is a refrigerated excursion in one hospital's 2026 investigational drug SOP (WVU Medicine, 2026).
What is investigational product accountability?
It is two regulations working together. 21 CFR 312.61 says the investigator gives the drug only to subjects under their personal supervision, or a subinvestigator's, and to no one else. 21 CFR 312.62(a) says the investigator records where every unit went: dates, quantity, and use by subject. When the study ends, unused supply goes back to the sponsor or is disposed of as the sponsor directs.
In practice the record has four parts that must tell the same story:
| Record | What it shows |
|---|---|
| Accountability log | Receipt, dispensing, returns, destruction, by kit and lot |
| Dosing or diary record | What the participant took, and when |
| Case history and EDC | What the site reported to the sponsor |
| Physical returns | What actually came back, opened or not |
Any one of them can be complete on its own and still wrong. The finding comes from the gap between them.
What FDA cites at sites
FDA's FY 2024 trend slides for clinical investigator inspections break the accountability citation into six sub-themes: missing records, missing use or exposure by subject, missing dates, inadequate or missing quantities, missing batch or code, and missing return, repair or disposition. On FDA's chart, three bars stand level at the top: missing return or disposition, missing use by subject, and wrong or missing quantity.
Product problems also appear under protocol compliance, the largest theme: randomization errors, kit selection errors, overdosing, underdosing, missed doses, and inadequate storage or preparation. An excursion nobody logged is a storage finding. A kit pulled from the wrong box is a protocol finding. Both start in the pharmacy, and both show up in the accountability record. Our guide to how an FDA inspection of a clinical trial site runs covers the other four themes.
The July 2026 warning letter: when the records disagree
The FDA Law Blog's August 11, 2026 summary of the letter, issued July 27 to a clinical investigator in Florida after a bioresearch monitoring inspection, cites 21 CFR 312.60 and 312.62(a). Two failures stand out.
First, one subject was enrolled in two investigational drug trials at once, for about six overlapping weeks. Second, for six subjects the dosing logs, the site's accountability records and the EDC did not match, and kits documented as dispensed and used came back with tamper-evident seals intact, which suggested they had never been opened.
The authors note that FDA treats drug accountability as far more than an administrative exercise. Read from the site's side, the useful point is how the problem surfaced: not from a missing entry, but from physical evidence contradicting a complete-looking record. A site that compares the returned product with the log at each visit would have seen the sealed kits the first time they came back.
Why the end-of-study count fails
Most sites reconcile when a monitor asks. That works when product sits in one locked cabinet. It works less well now. An October 1, 2026 piece in The Clinical Trial Vanguard describes product moving through central distributors, local pharmacies and couriers, with no single person owning the chain, and argues that sites should name a storage contact and a written escalation path to the sponsor's supply team before the site initiation visit.
FDA's September 2024 guidance on decentralized elements puts the duty plainly. When product goes directly to participants or local clinicians, "the investigator must authorize the release of the IP by the distributor," ensure receipt, and document the return or disposal of unused product. The same guidance says the drugs best suited for home shipment are those with good stability profiles. The more places the product goes, the less a once-a-visit count can catch. Our post on ICH E6(R3) Annex 2 covers what the international guideline adds for home dosing.
Six steps to keep the count current
- Name an owner for each study's product. One person, with a backup, who holds the log and is called when anything arrives, moves or warms up.
- Log receipt the day it arrives. Kit numbers, lot, expiry, quantity and the temperature record from the shipment, checked against the packing list before the product goes on the shelf.
- Record use by subject at the visit, not after. Dispensed kit, dose, date and the person who dispensed it, entered while the participant is still in the room.
- Write the excursion rule down before you need it. The range for each storage unit, what counts as an excursion, who is notified and where quarantined product goes.
- Reconcile every month, four ways. Log against dosing records against EDC against the physical returns. Count every returned kit and look at its seal; a sealed kit marked as used is a finding waiting to happen.
- Close every disposition. Returned or destroyed, with the date and the sponsor's authorization filed. Missing disposition was one of FDA's three leading accountability sub-themes in FY 2024.
The mistake most sites make at step 4
They treat the sponsor's excursion form as the procedure. The form tells you what to report; it does not tell you who checks the alarm on a Friday evening or where the product goes when the refrigerator fails. WVU Medicine's investigational drug service SOP, effective April 2, 2026, is a useful published example of a written rule. It sets refrigerated range at 2 to 8°C and counts an excursion as 1°C or more out of range for more than 30 minutes. Affected product is quarantined, moved to named backup storage with the time recorded, and held until the sponsor says whether to use, return or destroy it. Whatever your thresholds are, they belong in a site SOP before the first kit arrives, so that nobody decides them at the moment of the alarm.
Where this fits in site operations
Investigational product accountability sits beside the regulatory binder as one of the records an inspector reads first and a site keeps for years. Among the systems we build for clinical research sites is monitoring visit preparation: a checklist assembled from the monitoring plan that lists, for the coordinator and in time, the source expected since the last visit, open queries, regulatory items due and deviations to log. It does not replace the sponsor's supply system or the accountability log. It makes sure the gaps are found by the site first.
The log that agrees with the EDC, the dosing record and the returned kit is the only one that holds up. Check all four this month.
